281 related articles for article (PubMed ID: 9205769)
1. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
2. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
4. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
5. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
6. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
7. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
8. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
9. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[TBL] [Abstract][Full Text] [Related]
11. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Agut J; Sánchez JC; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-Helicobacter pylori activity of ebrotidine.
Palacín C; Tarragó C; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
[TBL] [Abstract][Full Text] [Related]
13. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
14. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
15. Physiological, immunohistochemical and molecular aspects of gastric adaptation to stress, aspirin and to H. pylori-derived gastrotoxins.
Konturek PC
J Physiol Pharmacol; 1997 Mar; 48(1):3-42. PubMed ID: 9098824
[TBL] [Abstract][Full Text] [Related]
16. Involvement of capsaicin-sensitive afferent nerves and cholecystokinin 2/gastrin receptors in gastroprotection and adaptation of gastric mucosa to Helicobacter pylori-lipopolysaccharide.
Brzozowski T; Konturek PC; Moran AP; Pajdo R; Kwiecien S; Konturek SJ; Sliwowski Z; Drozdowicz D; Pawlik WW; Hahn EG
J Pharmacol Exp Ther; 2004 Jul; 310(1):116-25. PubMed ID: 15024038
[TBL] [Abstract][Full Text] [Related]
17. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
18. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[TBL] [Abstract][Full Text] [Related]
19. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
[TBL] [Abstract][Full Text] [Related]
20. Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
Amagase K; Kato S; Yamamoto H; Okabe S
Arzneimittelforschung; 1996 Feb; 46(2):177-84. PubMed ID: 8720310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
